Italian Drug Approval Reform Shows Mixed Results on Negotiation Timelines
核心洞察
A new statistical analysis suggests Italy's AIFA (搜索) reform reduced drug price negotiation times from 483 to 388 days, representing a 95-day improvement using time-to-event methodology.
However, real-world data from 71 new drugs shows approval times actually increased to 495 days (16.5 months) in 2024-2026 compared to 439 days (14.6 months) in 2020-2023.
The conflicting findings highlight the importance of methodology in measuring regulatory performance, with researchers emphasizing their study was primarily designed to validate new analytical approaches rather than assess actual reform outcomes.
A new statistical analysis of Italy's pharmaceutical regulatory reform has produced conflicting results about drug approval timelines, with researchers claiming significant improvements while real-world data suggests longer wait times for patients.
Methodological Innovation Shows Apparent Improvement
Researchers led by Professor Pierluigi Navarra applied time-to-event statistical techniques to analyze AIFA (搜索)'s performance before and after the March 2024 reform. Using data from pharmaceutical intelligence company Intexo (搜索) covering all EMA-approved drugs from 2021-2023, the analysis found that negotiation duration fell from 483 days before the reform to 388 days after the reform - a reduction of 95 days.
When considering only the time between pharmaceutical companies' submission of price and reimbursement applications to AIFA (搜索) and procedure completion, the negotiation time was 188 days shorter in the post-reform period. The researchers noted that their time-to-event approach "has the advantage that it can also include procedures that have not yet been priced at the time of the analysis."
Real-World Data Contradicts Theoretical Improvements
However, analysis of actual AIFA (搜索) data tells a different story. Based on 71 new drugs (new chemical entities and new orphan drugs, excluding new indications) processed between June 2024 and January 2026, the average authorization pathway time from company application to Official Gazette publication was 495 days (16.5 months).
This represents an increase compared to the 2020-2023 period, when the average time from EMA approval to Official Journal publication was 439 days (14.6 months) according to Patient Wait Indicator data. The new timeline lags behind previous performance by approximately two months, with the analysis noting that times are counted from AIFA (搜索) application submission, which typically occurs 30-60 days after EMA approval.
Additional Delays Beyond Regulatory Approval
The real-world analysis emphasizes that regulatory approval represents only part of patient access timelines. In Italy, patients must additionally wait for Regional Registry access (between 90 and 150 days) and tender preparation and award processes before approved drugs become actually available.
Methodological Debate Highlights Measurement Challenges
The conflicting results underscore fundamental questions about how regulatory performance should be measured. The researchers acknowledged that "the primary objective of this study was the validation of a new methodology for analysing price negotiation times, to be proposed as an alternative to the simple descriptive statistics still in use today, and the results that have emerged have a case-study character for us, and are therefore entirely incidental."
Critics argue that patients need "precise timeframe between the date of EMA approval/application submission by companies and the final date, which for us in Italia coincides with the publication in the Official Gazette of the price and reimbursement determination approved by AIFA (搜索)'s Board of Directors." They emphasize that theoretical statistical models cannot replace "pragmatic, real and effective" data that reflects actual patient wait times.
Regulatory Response and Industry Impact
AIFA (搜索)'s Scientific Director Pierluigi Russo expressed satisfaction with the positive analytical results on LinkedIn, stating they "independently confirm our initial assessments." However, the disconnect between theoretical improvements and documented real-world performance raises questions about the reform's actual effectiveness.
The findings are being published in the journal Global and Regional Health Technology Assessment, with researchers expressing interest in the impact on industry experts. The debate highlights ongoing challenges in measuring and improving pharmaceutical access timelines across different healthcare systems.